On July 25, 2025 PDX Pharma reported it has successfully met the Year 1 milestones of its Phase II SBIR grant (R44CA285233) from the National Cancer Institute (NCI) for the development of PETTRA (PLK1 and EGFR Targeted Therapy and Radiation Sensitizer) for lung cancer treatment (Press release, PDX Pharmaceuticals, JUL 25, 2025, View Source [SID1234654548]). As a result, the NCI has issued a Notice of Award for approximately $1.09 million, bringing the total grant funding to $2.4 million. We thank the NCI for its continued support, as well as our dedicated staff and collaborators at OHSU, who worked tirelessly to achieve the project milestones. PETTRA demonstrated superior efficacy compared to the standard of care (SOC) in a metastatic non-small cell lung cancer (NSCLC) mouse model and exhibited strong synergy with radiation therapy. In the final phase of the project, we will conduct additional PK/PD and safety studies of PETTRA, advancing it toward clinical trials as both a monotherapy and a radiation sensitizer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!